Literature DB >> 27055135

Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT.

Pieterjan Gykiere1, Lode Goethals, Hendrik Everaert.   

Abstract

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein, which is frequently overexpressed on prostate cancer cells. A Ga-PSMA PET/CT can be used for early detection of lymph node or bone metastases after radical prostatectomy when there is biochemical recurrence. This report describes PSMA uptake in a healing fracture masquerading as metastatic bone disease in a patient with a history of prostate adenocarcinoma. Clinicians reporting Ga-PSMA PET/CT should be aware of this potential important pitfall.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27055135     DOI： 10.1097/RLU.0000000000001222

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  14 in total

1.  [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients.

Authors:  Jan-Carlo Janssen; Nadine Woythal; Sebastian Meißner; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

2.  Novel Structured Reporting Systems for Theranostic Radiotracers.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

3.  About the specificity of radiotracers for prostate cancer.

Authors:  Michael Soussan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-07       Impact factor: 9.236

4.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI.

Authors:  Liesbeth De Coster; Raf Sciot; Wouter Everaerts; Olivier Gheysens; Raf Verscuren; Christophe M Deroose; Steven Pans; Koen Van Laere; Karolien E Goffin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

Review 5.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

6.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 7.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

Review 8.  The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.

Authors:  Jie Jiang; Xiaoxia Tang; Yongzhu Pu; Yong Yang; Conghui Yang; Fake Yang; Yadong Tian; Jindan Li; Hua Sun; Sheng Zhao; Long Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

Review 9.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 10.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.